- Home
- PMAX vs INKT Comparison
PMAX vs INKT Comparison
Compare PMAX & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMAX
- INKT
- Stock Information
- Founded
- PMAX 2019
- INKT 2017
- Country
- PMAX Hong Kong
- INKT United States
- Employees
- PMAX N/A
- INKT N/A
- Industry
- PMAX
- INKT Medicinal Chemicals and Botanical Products
- Sector
- PMAX
- INKT Health Care
- Exchange
- PMAX Nasdaq
- INKT Nasdaq
- Market Cap
- PMAX 7.9M
- INKT 28.9M
- IPO Year
- PMAX 2024
- INKT 2021
- Fundamental
- Price
- PMAX $0.50
- INKT $7.04
- Analyst Decision
- PMAX
- INKT Strong Buy
- Analyst Count
- PMAX 0
- INKT 2
- Target Price
- PMAX N/A
- INKT $37.50
- AVG Volume (30 Days)
- PMAX 1.5M
- INKT 14.7K
- Earning Date
- PMAX 04-28-2025
- INKT 08-12-2025
- Dividend Yield
- PMAX N/A
- INKT N/A
- EPS Growth
- PMAX N/A
- INKT N/A
- EPS
- PMAX N/A
- INKT N/A
- Revenue
- PMAX $4,694,079.00
- INKT N/A
- Revenue This Year
- PMAX N/A
- INKT N/A
- Revenue Next Year
- PMAX N/A
- INKT N/A
- P/E Ratio
- PMAX N/A
- INKT N/A
- Revenue Growth
- PMAX N/A
- INKT N/A
- 52 Week Low
- PMAX $0.28
- INKT $4.56
- 52 Week High
- PMAX $4.70
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- PMAX N/A
- INKT 47.56
- Support Level
- PMAX N/A
- INKT $6.91
- Resistance Level
- PMAX N/A
- INKT $7.51
- Average True Range (ATR)
- PMAX 0.00
- INKT 0.32
- MACD
- PMAX 0.00
- INKT -0.02
- Stochastic Oscillator
- PMAX 0.00
- INKT 27.28
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.